Wikipedia

Aurodox

Aurodox (X-5108, Goldinomycin) is a naturally occurring polyketide antibiotic drug, first isolated in 1972 from Streptomyces goldiniensis. It is active against various species of Gram-positive bacteria through inhibition of the type III secretion system (T3SS), and while its chemical properties make it unsuitable for use in human medicine directly, it is used in antibiotic research and related compounds may be developed for medical use.[1][2][3]

Aurodox
Legal status
Legal status
  • Investigational
Identifiers
  • (2S)-N-[(2E,4E,6S,7R)-7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-[(1E,3E,5E)-7-(4-hydroxy-1-methyl-2-oxopyridin-3-yl)-6-methyl-7-oxohepta-1,3,5-trienyl]oxolan-2-yl]-6-methoxy-5-methylocta-2,4-dienyl]-2-[(2R,3R,4R,6S)-2,3,4-trihydroxy-5,5-dimethyl-6-[(1E,3Z)-penta-1,3-dienyl]oxan-2-yl]butanamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC44H62N2O12
Molar mass810.982 g·mol−1
3D model (JSmol)
  • CC[C@H](C(=O)NC/C=C/C=C(\C)/[C@H]([C@@H](C)[C@H]1[C@H]([C@H]([C@H](O1)/C=C/C=C/C=C(\C)/C(=O)C2=C(C=CN(C2=O)C)O)O)O)OC)[C@@]3([C@@H]([C@@H](C([C@@H](O3)/C=C/C=C\C)(C)C)O)O)O
  • InChI=1S/C44H62N2O12/c1-10-12-14-22-32-43(6,7)39(51)40(52)44(55,58-32)29(11-2)41(53)45-24-18-17-20-27(4)37(56-9)28(5)38-36(50)35(49)31(57-38)21-16-13-15-19-26(3)34(48)33-30(47)23-25-46(8)42(33)54/h10,12-23,25,28-29,31-32,35-40,47,49-52,55H,11,24H2,1-9H3,(H,45,53)/b12-10-,15-13+,18-17+,21-16+,22-14+,26-19+,27-20+/t28-,29-,31-,32+,35+,36+,37-,38+,39+,40-,44-/m1/s1
  • Key:NTAHMPNXQOYXSX-WKSONYIQSA-N

See also

edit

References

edit
  1. ^ McHugh RE, O'Boyle N, Connolly JP, Hoskisson PA, Roe AJ (February 2019). "Characterization of the Mode of Action of Aurodox, a Type III Secretion System Inhibitor from Streptomyces goldiniensis". Infection and Immunity. 87 (2). doi:10.1128/IAI.00595-18. PMC 6346137. PMID 30455200.
  2. ^ Kimishima A, Hagimoto D, Honsho M, Watanabe Y, Iwatsuki M, Tsutsumi H, et al. (August 2022). "Insights into the structure-activity relationship of a type III secretion system inhibitor, aurodox". Bioorganic & Medicinal Chemistry Letters. 69: 128779. doi:10.1016/j.bmcl.2022.128779. PMID 35545199.
  3. ^ Watanabe Y, Haneda T, Kimishima A, Kuwae A, Suga T, Suzuki T, et al. (April 2024). "PurA is the main target of aurodox, a type III secretion system inhibitor". Proceedings of the National Academy of Sciences of the United States of America. 121 (17): e2322363121. Bibcode:2024PNAS..12122363W. doi:10.1073/pnas.2322363121. PMC 11046696. PMID 38640341.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Aurodox&oldid=1247017595"